The use of numbers needed to treat derived from systematic reviews and meta-analysis: Caveats and pitfalls

Evaluation and the Health Professions

Volumn 24, Issue 2, 2001, Pages 152-164

  Ebrahim, S ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCULATION; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; FATALITY; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT;

CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; META-ANALYSIS; METHODS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0035177738     PISSN: 01632787     EISSN: None     Source Type: Journal    
DOI: 10.1177/01632780122034858     Document Type: Review

References (29)

1. Confidence intervals for the number needed to treat
2. The Cochrane database of systematic reviews [Disk and CD-ROM]
3. The number needed to treat: A clinically useful measure of treatment effect
4. Same information, different decisions: The influence of evidence on the management of hypertension in the elderly
5. Review: Statins prevent stroke, especially in patients with coronary heart disease
6. Meta-analysis. Unresolved issues and future developments
7. Meta-analysis: Beyond the grand mean?
8. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TEXCAPS
9. Numbers needed to treat: Does it help clinical decision making?
10. Meta-analysis: Principles and procedures
11. Evidence based purchasing: Understanding results of clinical trials and systematic reviews
12. The statistical basis of meta-analysis
13. Communicating the benefits of chronic preventative therapy: Does the format of efficacy data determine patients' acceptance of treatment?
14. Five-year findings of the Hypertension Detection and Follow-up Program. II. Mortality by race-sex and age
15. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials
16. An assessment of clinically useful measures of the consequences of treatment
17. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
18. General practitioners' perceptions of the route to evidence based medicine: A questionnaire survey
19. Medical Research Council trial of treatment of hypertension in older adults: Principal results
20. Hypertension in the elderly. Implications and generalizability of randomized trials
21. Measured enthusiasm: Does the method of reporting trial results alter perceptions of therapeutic effectiveness?
22. Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy
23. Can overall results of clinical trials be applied to all patients?
24. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
25. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
26. British regional heart study: Cardiovascular risk factors in middle-aged men in 24 towns
27. The relation between treatment benefit and underlying risk in meta-analysis
28. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
29. Numbers needed to treat from metaanalyses - Sometimes informative, usually misleading